# Julien Taı̈eb

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/julien-ta-eb/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,508 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 93 |
| i10-index | 440 |
| Last Known Institution | Université Paris Cité |
| OpenAlex ID | https://openalex.org/A5024180743 |
| ORCID iD | https://orcid.org/0000-0002-9955-4753 |
| Works | 1,263 |

## Researcher papers

- [VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors](https://scholariq.org/papers/vegf-a-modulates-expression-of-inhibitory-checkpoints-on-cd8-t-cells-in-tumors/)
- [Duration of Adjuvant Chemotherapy for Stage III Colon Cancer](https://scholariq.org/papers/duration-of-adjuvant-chemotherapy-for-stage-iii-colon-cancer/)
- [FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis](https://scholariq.org/papers/folfirinox-for-locally-advanced-pancreatic-cancer-a-systematic-review-and/)
- [Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer](https://scholariq.org/papers/trifluridine-tipiracil-and-bevacizumab-in-refractory-metastatic-colorectal/)
- [First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials](https://scholariq.org/papers/first-line-selective-internal-radiotherapy-plus-chemotherapy-versus-chemotherapy/)
- [Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial](https://scholariq.org/papers/oxaliplatin-fluorouracil-and-leucovorin-with-or-without-cetuximab-in-patients/)
- [Identification of CD8 <sup>+</sup> CD25 <sup>+</sup> Foxp3 <sup>+</sup> suppressive T cells in colorectal cancer tissue](https://scholariq.org/papers/identification-of-cd8-sup-sup-cd25-sup-sup-foxp3-sup-sup-suppressive-t-cells-in/)
- [Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)](https://scholariq.org/papers/early-evaluation-of-circulating-tumor-dna-as-marker-of-therapeutic-efficacy-in/)
- [Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial](https://scholariq.org/papers/three-versus-6-months-of-oxaliplatin-based-adjuvant-chemotherapy-for-patients/)
- [Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)](https://scholariq.org/papers/pancreatic-cancer-french-clinical-practice-guidelines-for-diagnosis-treatment/)
- [Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study](https://scholariq.org/papers/efficacy-of-adjuvant-chemotherapy-in-colon-cancer-with-microsatellite/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Surgical Treatments](https://scholariq.org/topics/colorectal-cancer-surgical-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Université Paris Cité](https://scholariq.org/institutions/universite-paris-cite/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.